I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00. UBS Group currently has a buy rating ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. "Yes, I Can And Have Had Sex": People With Quadriplegia Are Opening ...